Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (279)	2/24/2007 7:14:56 PM
From: tuck	Respond to of 360

Steve, You're thinking of Rosetta Inpharmatics, munched by Merck. Merck let their new little sub keep their name on publications, at least, and Rosetta made some news a couple of years ago by doing a study pointing to off-target effects of siRNA. Which didn't stop Merck from subsequently munching Sirna Therapeutics a couple of years later. Cheers, Tuck

To: Steve Lokness who wrote (279)	2/25/2007 4:28:13 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

OT Yup, but naturally the name caught my eye when I noticed it in the list of IPO stuff available coming up to etrade customers. It does not look like they'll get much of a valuation, the new lowered price will be around $8 and the offering is 3.8M shares. You will recognize two names on the SAB (Langer and Levine). rosettagenomics.com Anyway, the original Rosetta, Rosetta Inpharmatics went away at what, $600M or something like that. This one, Rosetta Genomics, is becoming listed at something on the order of $30M and that seems awfully small to even bother with an IPO. Of course RI and RG have nothing to do with each other, and I'd never have heard of if it they hadn't picked the great name. I couldn't tell you the names of any Israeli biotechs otherwise. They have two ties to Rockefeller, plus a license with Rockefeller. Your trivia for the day is that Levine also happens to be on the BOD of Infinity. Anyway, here is a PR from last June: REHOVOT, Israel, June 14 /PRNewswire/ -- Rosetta Genomics and Rockefeller University today announced the signing of a licensing agreement that will allow Rosetta Genomics to access nearly 180 proprietary microRNAs from Rockefeller University. These microRNAs will be added to Rosetta Genomics's microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs. Under the terms of the agreement, Rosetta Genomics will be able to use these microRNAs to potentially advance multiple research development programs targeting new microRNA based diagnostic tools for a variety of diseases. If I can snag a few hundred shares through etrade that'll be fun--I wont follow the company unless I own a few shares. Plus, it has been years since I put in for any IPOs. Etrade might not even let me have any, I've been inactive for so long. Can always buy it after it comes out, it isn't as if they've been gapping up or anything. Could even sag after a few days and be cheaper than what I'd offer.